{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Serper M"],"funding":["NCATS NIH HHS","CSRD VA"],"pagination":["1954-1964"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5664153"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["152(8)"],"pubmed_abstract":["<h4>Background & aims</h4>Little is known about provider and health system factors that affect receipt of active therapy and outcomes of patients with hepatocellular carcinoma (HCC). We investigated patient, provider, and health system factors associated with receipt of active HCC therapy and overall survival.<h4>Methods</h4>We performed a national, retrospective cohort study of all patients diagnosed with HCC from January 1, 2008 through December 31, 2010 (n = 3988) and followed through December 31 2014 who received care through the Veterans Administration (128 centers). Outcomes were receipt of active HCC therapy (liver transplantation, resection, local ablation, transarterial therapy, or sorafenib) and overall survival.<h4>Results</h4>In adjusted analyses, receiving care at an academica"],"journal":["Gastroenterology"],"pubmed_title":["Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality."],"pmcid":["PMC5664153"],"funding_grant_id":["I01 CX000981","UL1 TR001863"],"pubmed_authors":["Aytaman A","Mehta R","Fox R","Valderrama A","Kaplan DE","Serper M","D'Addeo K","Dai F","Taddei TH","Goldberg DS","Baytarian M","VOCAL Study Group","Hunt K"],"additional_accession":[]},"is_claimable":false,"name":"Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.","description":"<h4>Background & aims</h4>Little is known about provider and health system factors that affect receipt of active therapy and outcomes of patients with hepatocellular carcinoma (HCC). We investigated patient, provider, and health system factors associated with receipt of active HCC therapy and overall survival.<h4>Methods</h4>We performed a national, retrospective cohort study of all patients diagnosed with HCC from January 1, 2008 through December 31, 2010 (n = 3988) and followed through December 31 2014 who received care through the Veterans Administration (128 centers). Outcomes were receipt of active HCC therapy (liver transplantation, resection, local ablation, transarterial therapy, or sorafenib) and overall survival.<h4>Results</h4>In adjusted analyses, receiving care at an academica","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jun","modification":"2025-04-20T03:36:14.477Z","creation":"2019-03-26T23:38:58Z"},"accession":"S-EPMC5664153","cross_references":{"pubmed":["28283421"],"doi":["10.1053/j.gastro.2017.02.040"]}}